中文

兴齐眼药 Revenue Breakdown

Period 2026-03-31 ・ Reported 2026-04-28
ItemAmountY/Y
Revenue¥0.68B+27.5%
Gross profit¥0.56B
Operating income¥0.23B
Net income¥0.21B+41.5%
Gross margin82.1%Net margin 30.2%
Revenue Q/Q+20.1%

Revenue Segments

The filing did not disclose a revenue breakdown for this period.

Costs & Expenses

ItemAmount% of revenue
Cost of revenue¥0.12B17.9%
R&D¥0.08B12.4%
SG&A¥0.24B35.3%
Tax & other¥0.03B3.8%
Generate the full Sankey chart →

The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.

Other companies

中旗股份容大感光开润股份会畅科技数字认证贝斯特晨曦航空英飞特赛托生物海辰药业奥联电子美联新材

Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies